



Biomarker and AI-supported FX06 therapy to prevent the progression from mild and moderate to severe stages of COVID-19




FX06 – an innovative therapy against capillary leak




Research

- IXION phase II trial
- Immuno-biomarker profiling
- Endothelial cells assessment



Development

- Drug production
- AI decision support models
- Personalised medication





Outreach

- FX06 therapy
- AI-based tools for healthcare workers
- Clinical guidelines

17 partners



@COVend_EU
covend-project.eu



Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.